July 16, 2019

Via Electronic Submission

Norman E. Sharpless, M.D., Commissioner
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993-0002

Re: Docket No. FDA–2019–N–1482
Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds

Dear Commissioner Sharpless,

We, the undersigned State Attorneys General, submit this comment in response to the Food and Drug Administration’s (“FDA”) requests for comments on the safety, manufacturing, and sale of products containing cannabis or cannabis-derived compounds.1 Importantly, in considering regulation of products that contain cannabis or cannabis-derived compounds, including cannabidiol (CBD), the FDA should continue to incorporate State Attorneys General feedback and ensure that states maintain a role as regulators in this emerging market.

As the primary enforcers of our respective states’ consumer protection laws, we offer a unique perspective as to the new legalized market of certain cannabis and cannabis-derived compounds, including CBD products. We write to express our hope that the FDA continues to explore manufacturing, testing, and marketing best practices so that consumers are not at risk of misleading advertising or harm to their health from dangerous additives or undisclosed risks of use. Although products containing cannabis or cannabis-derived compounds may well offer real benefits to consumers, it is important that consumers have reliable risk and benefit information to make informed choices about initiating and continuing the use of these products. A crucial element of FDA regulation and oversight should be an on-going assessment of the potential risks or benefits of these products, particularly for specific populations such as pregnant women, adolescents and children, and the elderly. How these products interact with other dietary or pharmaceutical products should be included in this assessment. It is also important that companies not mislead consumers. Scientific and medical data from the FDA would assist in meaningful enforcement of advertising laws and regulations by the states.

Currently, companies are creating a myriad of cannabinoid products largely unburdened by any oversight or testing requirements. The inherent complexity of cannabinoids, combined with the danger of hazardous additives, raises

1 See Request for Comments, Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds, 84 Fed. Reg. 12,969 (April 3, 2019).
serious public health concerns that absent some rules or regulations, unscrupulous companies will be able to distribute products that include illegal cannabinoid combinations or have dangerous additives.

Beyond these dangers, there is also the potential for products to be incorrectly or misleadingly labeled and packaged in ways that take advantage of consumers and puts them at risk. Although many operational companies making cannabis and CBD products appropriately test, package, and label their products, some do not. These products should be subject to testing and manufacturing guidelines in order to keep consumers appropriately informed and safe.

Ultimately, the responsibility for protecting consumers that use cannabinoids and CBD products cannot solely be left to the companies supplying products—that responsibility must include the FDA with meaningful partnerships with the states and State Attorneys General. We applaud the FDA’s recent steps, including the formation of the CBD working group focused on exploring pathways for dietary supplements and food regulation, seeking to clarify code citations, regulating cosmetics, and researching existing science and developments.

We appreciate the FDA’s willingness to listen to and consult with State Attorneys General on regulation of cannabinoids and CBD products. We hope that the FDA will continue to recognize the important role that states play in this emerging market, and that the FDA will incorporate the ongoing feedback that State Attorneys General provide.

Sincerely,

Karl A. Racine  
District of Columbia Attorney General

Mike Hunter  
Oklahoma Attorney General

Steve Marshall  
Alabama Attorney General

Kevin G. Clarkson  
Alaska Attorney General

Xavier Becerra  
California Attorney General

Phil Weiser  
Colorado Attorney General

William Tong  
Connecticut Attorney General

Kathleen Jennings  
Delaware Attorney General
Leevin Taitano Camacho  
Guam Attorney General

Clare E. Connors  
Hawaii Attorney General

Lawrence Wasden  
Idaho Attorney General

Kwame Raoul  
Illinois Attorney General

Tom Miller  
Iowa Attorney General

Andy Beshear  
Kentucky Attorney General

Jeff Landry  
Louisiana Attorney General

Aaron M. Frey  
Maine Attorney General

Brian Frosh  
Maryland Attorney General

Maura Healey  
Massachusetts Attorney General

Dana Nessel  
Michigan Attorney General

Keith Ellison  
Minnesota Attorney General

Jim Hood  
Mississippi Attorney General

Tim Fox  
Montana Attorney General

Douglas Peterson  
Nebraska Attorney General

Gurbir S. Grewal  
New Jersey Attorney General

Hector Balderas  
New Mexico Attorney General

Letitia James  
New York Attorney General
Josh Stein
North Carolina Attorney General

Wayne Stenehjem
North Dakota Attorney General

Edward Manibusan
Northern Mariana Islands Attorney General

Dave Yost
Ohio Attorney General

Ellen F. Rosenblum
Oregon Attorney General

Josh Shapiro
Pennsylvania Attorney General

Peter F. Neronha
Rhode Island Attorney General

Herbert H. Slatery III
Tennessee Attorney General

T.J. Donovan
Vermont Attorney General

Mark R. Herring
Virginia Attorney General

Robert W. Ferguson
Washington Attorney General